Screener
Immunome IMNM Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 31,106 | 48,845 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 113,171,396 and 113,133,199 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 1,370,678 | 1,362,496 |
| Accumulated deficit | (782,003) | (728,164) |
| Total stockholders’ equity | 588,686 | 634,343 |
| Total liabilities and stockholders’ equity | $619,792 | $683,188 |
Item 1. Financial Statements.
FAQ
- What is Immunome's total equity?
- Immunome (IMNM) reported total equity of $588.69M in Q1 2026.
- How has Immunome's total equity changed year-over-year?
- Immunome's total equity increased by 91.7% year-over-year, from $307.13M to $588.69M.
- What is the long-term trend for Immunome's total equity?
- Over 5 years (2020 to 2025), Immunome's total equity has grown at a 72.7% compound annual growth rate (CAGR), from $41.35M to $634.34M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Immunome's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude